Silex Systems: Pioneering Innovations in Nuclear Energy, Quantum Silicon, and Medical Isotopes.

Silex Systems Limited (ASX: SLX) is advancing its innovative SILEX laser enrichment technology across uranium, silicon, and medical isotope applications. Significant progress has been made in the uranium enrichment project with Global Laser Enrichment (GLE), including commissioning full-scale pilot equipment in Wilmington, NC, with technology demonstration (TRL-6) targeted by year-end 2024. This initiative aims to address global nuclear fuel supply chain challenges amid rising demand for clean energy and energy security.

Additionally, Silex is developing a Quantum Silicon production plant at its Lucas Heights facility, backed by federal funding and support from Silicon Quantum Computing (SQC). In the medical domain, the company completed Stage 1 of its MIST project, achieving proof-of-concept for producing enriched Ytterbium-176, a key precursor for advanced cancer treatments. These developments underscore Silex’s role in addressing critical global needs in energy, quantum computing, and healthcare while navigating associated risks and uncertainties.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com